Aloufi M, Alzahrany G, Abdulmajeed N, Alzahrani S, Alghwery S, Zahid R, Alghamdi A
Pediatric Nephrology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Pediatric Nephrology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Transplant Proc. 2019 Mar;51(2):522-525. doi: 10.1016/j.transproceed.2019.01.010. Epub 2019 Jan 4.
Viral infections are known to be common complications after kidney transplant (KTx), causing significant numbers of mortality and morbidity.
We aimed to highlight the pattern of viral infections after KTx in children and its impact on allograft function.
We included children who underwent KTx between 2012 and 2017. Baseline demographics, immunosuppressive agents, episodes of viral infections with cytomegalovirus (CMV), BK virus, and Epstein-Barr virus (EBV), and serum creatinine were collected. All children received induction agent followed by maintenance immunosuppression. Oral valganciclovir was given to all high-risk patients for CMV for 180 days as prophylaxis. CMV and EBV polymerase chain reactions were monitored every 2 weeks initially until the ninth month, then monthly until the end of the second year, and then every 3 months. Urine BKV polymerase chain reactions were monitored monthly in the first year and then every 3 months.
A total of 18 children received transplants. There was 1 episode of CMV infection (5.6%), 2 episodes (11.1%) of isolated BK viruria (1 of the 2 with an episode of BK viremia [5.6%] with no associated BK nephropathy [0%]), and no episodes of EBV or lymphoproliferative disease (0%). Allograft functions continued to be stable with mean serum creatinine of 52.2 μmol/L during the study period with 2 episodes (11.1%) of acute cellular rejection and 1 episode (5.6%) of early antibody-mediated rejection.
Prolonged prophylaxis and strict viral monitoring protocol can be effective ways of controlling viral infections after KTx.
病毒感染是肾移植(KTx)后常见的并发症,会导致大量死亡和发病。
我们旨在突出儿童肾移植后病毒感染的模式及其对移植肾功能的影响。
我们纳入了2012年至2017年间接受肾移植的儿童。收集了基线人口统计学资料、免疫抑制剂、巨细胞病毒(CMV)、BK病毒和EB病毒(EBV)感染发作情况以及血清肌酐。所有儿童均接受诱导剂治疗,随后进行维持性免疫抑制。所有CMV高危患者均接受口服缬更昔洛韦预防180天。最初每2周监测一次CMV和EBV聚合酶链反应,直至第九个月,然后每月监测一次直至第二年结束,之后每3个月监测一次。第一年每月监测尿BKV聚合酶链反应,之后每3个月监测一次。
共有18名儿童接受了移植。发生1例CMV感染(5.6%),2例孤立性BK病毒尿(2例中的1例伴有BK病毒血症发作[5.6%],无相关BK肾病[0%]),无EBV或淋巴增殖性疾病发作(0%)。在研究期间,移植肾功能持续稳定,平均血清肌酐为52.2μmol/L,发生2例急性细胞排斥反应(11.1%)和1例早期抗体介导的排斥反应(5.6%)。
延长预防时间和严格的病毒监测方案可能是控制肾移植后病毒感染的有效方法。